Microcirculatory Guided Goal Directed Fluid Therapy in Septic Shock; a Feasibility Study (MICRORESUS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03898674 |
|
Recruitment Status : Unknown
Verified March 2019 by King's College London.
Recruitment status was: Recruiting
First Posted : April 2, 2019
Last Update Posted : April 2, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Septic Shock | Drug: Intra venous fluid | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Feasibility study - single arm |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Microcirculatory Guided Goal Directed Fluid Therapy in Septic Shock; a Feasibility Study |
| Actual Study Start Date : | February 5, 2019 |
| Estimated Primary Completion Date : | October 1, 2020 |
| Estimated Study Completion Date : | October 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: GDT feasibility
Patients undergoing microcirculatory goal directed therapy
|
Drug: Intra venous fluid
Volume of intra venous fluid administered during GDT protocol |
- Time to acquire POEM score [ Time Frame: 6 hours ]Feasibility measure of point of care test
- Effect of POEM score on clinical decision making [ Time Frame: 6 hours ]Feasibility outcome measure
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Age > 18 years Within 6 hours of ICU admission Evidence of suspected or confirmed infection Serial Organ Failure Assessment (SOFA) score increase of 2 or more (assuming baseline 0 if no previous measures) Requiring vasopressor therapy to maintain a MAP > 65mmHg Lactate > 2 mmol/l despite initial fluid resuscitation Requirement for advanced haemodynamic monitoring (PiCCO system) in the opinion of the attending clinician
Exclusion Criteria:
Patients not expected to survive 24 h in whom the intent of treatment is palliative Patients in whom the primary cause of the shock state is cardiogenic
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03898674
| Contact: Sam Hutchings, PhD | 07832678654 | sam.hutchings@nhs.net |
| United Kingdom | |
| King's College Hospital NHS Foundation Trust | Recruiting |
| London, United Kingdom, SE5 9RS | |
| Contact: Sam Hutchings, PhD sam.hutchings@nhs.net | |
| Responsible Party: | King's College London |
| ClinicalTrials.gov Identifier: | NCT03898674 |
| Other Study ID Numbers: |
40180 |
| First Posted: | April 2, 2019 Key Record Dates |
| Last Update Posted: | April 2, 2019 |
| Last Verified: | March 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Shock, Septic Shock Pathologic Processes Sepsis |
Infections Systemic Inflammatory Response Syndrome Inflammation |

